Dietary Polyphenols as Adjunctive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- 1The First Clinical Medical College, Anhui University of Chinese Medicine, Hefei 230012, China
- 2College of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei 230012, China
Abstract
Background: Dietary polyphenols have been studied as adjunctive therapies for inflammatory bowel disease (IBD), but trials vary in formulation, clinical setting, and outcome definitions. We evaluated efficacy and safety separately for ulcerative colitis (UC) and Crohn’s disease (CD). Methods: We searched MEDLINE/PubMed, China National Knowledge Infrastructure (CNKI), Wanfang, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov through 20 August 2026. Risk of bias was assessed using Cochrane Risk of Bias 2 (RoB 2). Meta-analyses used MDs, SMDs, or ORs with 95% CIs. Quantitative synthesis was undertaken when studies were sufficiently comparable in clinical setting, outcome definition, and data structure; otherwise, results were summarized using study-level estimates. The protocol was registered with PROSPERO (CRD420261451126). Results: Twenty-one reports representing 19 randomized trials and 1048 participants were included. In conventional UC, polyphenols were associated with lower SCCAI scores (MD −1.32, 95% CI −1.81 to −0.83; I2 = 0%), whereas CRP/hs-CRP did not show a clear pooled effect (SMD 0.29, 95% CI −0.32 to 0.90; I2 = 83.7%). IBDQ-9 improved (MD 5.57, 95% CI 2.88 to 8.26). Clinical response favored supplementation (OR 4.90, 95% CI 3.04 to 7.89), as did induction of clinical remission (OR 5.98, 95% CI 3.08 to 11.59; I2 = 22.6%). Supplementation also favored endoscopic remission (OR 10.81, 95% CI 1.67 to 69.93; I2 = 69.4%), but the estimate was imprecise and sensitive to study-level risk of bias. In CD, the two randomized trials were not pooled due to targeting different clinical settings. Safety reporting was heterogeneous and sparse, with no consistent pattern of increased harm across trials. Conclusions: Curcumin has the most extensive adjunctive evidence base in UC but effect estimates for several outcomes were imprecise or sensitive to study design. Evidence in CD is still lacking.
Related
- Differential Impacts of Platelet-Rich Plasma and Hyaluronic Acid on miR-132 Modulation, Inflammatory Cytokines (IL-1β and IL-6), and Functional Recovery in Knee Osteoarthritis: A Randomized Controlled Trial
- Can physical exercise improve allergic rhinitis symptoms in adults? A systematic review of randomized controlled trials
- Hemoadsorption to prevent acute kidney injury in elective cardiac surgery: a systematic review of randomized controlled trials with meta-analysis and trial sequential analysis
- Hydrolyzed Rice Formula for the Management of Cow’s Milk Allergy in Infants and Young Children: A Systematic Review of Randomized Controlled Trials
- Biologics and small molecules for perianal Crohn’s disease: a systematic review and meta-analyses of randomized placebo-controlled trials
BibTeX
@article{dong2026dietary,
title = {{Dietary Polyphenols as Adjunctive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials}},
author = {Yuang Dong and Huitong Xu and Dongyang Zhang and Xinxin Ren and Xinyu Wu and Zhou Zheng and Qingsheng Yu and Yi Shen},
journal = {Nutrients},
year = {2026},
month = oct,
doi = {10.3390/nu18203335},
url = {https://www.mdpi.com/2072-6643/18/20/3335},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Dietary Polyphenols as Adjunctive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
AU - Yuang Dong
AU - Huitong Xu
AU - Dongyang Zhang
AU - Xinxin Ren
AU - Xinyu Wu
AU - Zhou Zheng
AU - Qingsheng Yu
AU - Yi Shen
PY - 2026
DA - 2026/10/01
JO - Nutrients
DO - 10.3390/nu18203335
UR - https://www.mdpi.com/2072-6643/18/20/3335
AB - Background: Dietary polyphenols have been studied as adjunctive therapies for inflammatory bowel disease (IBD), but trials vary in formulation, clinical setting, and outcome definitions. We evaluated efficacy and safety separately for ulcerative colitis (UC) and Crohn’s disease (CD). Methods: We searched MEDLINE/PubMed, China National Knowledge Infrastructure (CNKI), Wanfang, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov through 20 August 2026. Risk of bias was assessed using Cochrane Risk of Bias 2 (RoB 2). Meta-analyses used MDs, SMDs, or ORs with 95% CIs. Quantitative synthesis was undertaken when studies were sufficiently comparable in clinical setting, outcome definition, and data structure; otherwise, results were summarized using study-level estimates. The protocol was registered with PROSPERO (CRD420261451126). Results: Twenty-one reports representing 19 randomized trials and 1048 participants were included. In conventional UC, polyphenols were associated with lower SCCAI scores (MD −1.32, 95% CI −1.81 to −0.83; I2 = 0%), whereas CRP/hs-CRP did not show a clear pooled effect (SMD 0.29, 95% CI −0.32 to 0.90; I2 = 83.7%). IBDQ-9 improved (MD 5.57, 95% CI 2.88 to 8.26). Clinical response favored supplementation (OR 4.90, 95% CI 3.04 to 7.89), as did induction of clinical remission (OR 5.98, 95% CI 3.08 to 11.59; I2 = 22.6%). Supplementation also favored endoscopic remission (OR 10.81, 95% CI 1.67 to 69.93; I2 = 69.4%), but the estimate was imprecise and sensitive to study-level risk of bias. In CD, the two randomized trials were not pooled due to targeting different clinical settings. Safety reporting was heterogeneous and sparse, with no consistent pattern of increased harm across trials. Conclusions: Curcumin has the most extensive adjunctive evidence base in UC but effect estimates for several outcomes were imprecise or sensitive to study design. Evidence in CD is still lacking.
SN - 2072-6643
ER -